Breaking News

Financial Report: Baxalta

February 17, 2016

Revenues up 5% in the quarter

4Q Revenues: $1.8 billion (+5%)
4Q Earnings: $95 million (earnings were $763 million 4Q14)
FY Revenues: $6.1 billion (+3%)
FY Earnings: $956 million (-47%)
Hematology revenues were $1.0 billion in the quarter, down 2%. Immunology revenues were $680 million, up 8%. Oncology revenues were $53 million from the acquisition of ONCASPAR (pegaspargase) leukemia portfolio from Sigma-Tau. Results include after-tax special items totaling $292 million, primarily for asset repayment, expenses associated with the company’s separation from Baxter International, and certain business development and collaboration-related items.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks